Alerta

VACCINE COMPOSITION COMPRISING A SYSTEM FOR DELIVERING AN INACTIVATED WHOLE BACTERIUM VIA CATIONIC POLYSACCHARIDE NANOPARTICLES WITHOUT ANY ADJUVANT

Resumen de: MX2025009500A

The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.

Salmonella drug resistance monitoring data safety management system based on block chain

Resumen de: CN120567452A

The invention provides a salmonella drug resistance monitoring data security management system based on a block chain, and belongs to the technical field of data transmission management. A hierarchical encryption mechanism is constructed, the technical characteristics of the block chain are fused, a standardized feature combination template architecture is designed, and a matched hierarchical transmission and intelligent contract verification system is used; a differential encryption strategy is implemented on the basis of data sensitivity, and the security of each level of data is guaranteed in combination with symmetric and asymmetric encryption technologies; through characteristic parameter modularization recombination and template association identification, data integrity is guaranteed, transmission efficiency is optimized at the same time, and scattered data can be precisely restored into a structured data set; and finally, through consensus node verification driven by an intelligent contract and on-chain state updating, whole-process standardized management and control of data from collection, transmission to storage are realized, and a salmonella drug resistance monitoring data security management mode with security, efficiency and traceability is constructed.

Arachidonic acid ethanolamine composition and application thereof

Resumen de: CN120569193A

The composition containing the arachidonic acid ethanolamine or the derivatives of the arachidonic acid ethanolamine is used for preparing nutritional supplements, health-care products, foods and beverages for regulating intestinal flora, the level of a first intestinal microbiota in a subject can be remarkably improved, meanwhile, the level of a second intestinal microbiota in the subject is reduced, and then intestinal health is improved. The first intestinal microbiota is selected from one or more of the following groups: Rosella, Bacteroides and Prevotella; the second intestinal microbiota is salmonella or escherichia coli.

Lactobacillus plantarum RT1 with anti-inflammatory function and application thereof

Resumen de: CN120555287A

The invention discloses a lactobacillus plantarum RT1 with an anti-inflammatory effect and application of the lactobacillus plantarum RT1. The lactobacillus plantarum RT1 with the anti-inflammatory effect is screened by utilizing a J774-Dual macrophage inflammation model, the influence of the RT1 on the cell activity is evaluated, and the anti-inflammatory effect of the lactobacillus plantarum RT1 is researched. It is found that the lactobacillus plantarum RT1 significantly inhibits LPS and salmonella induced NF-kappa B activation, inhibits expression of pro-inflammatory cytokines IL-1beta, TNF-alpha and IL-6, meanwhile up-regulates the expression level of an anti-inflammatory cytokine IL-10, and maintains good cell activity; dSS-induced weight loss, occult blood, colon shortening and DAI score are significantly relieved, the MPO level and inflammatory cytokine expression are reduced, and colon tissue pathological damage is improved. The lactobacillus plantarum RT1 has the function of inhibiting intestinal inflammation, so that a new material is provided for the development of novel efficient anti-inflammatory probiotics.

Microbial treatment flora for treating odor of household garbage treatment station

Resumen de: CN120555263A

The invention discloses a microbiological treatment flora for treating odor of a household garbage treatment station. Comprising the following microbial treatment flora components: 12 to 33 percent of biphasic photosynthetic bacteria, 0.2 to 1.5 percent of clostridium butyricum, 8 to 22 percent of bifidobacterium, 0.2 to 1.5 percent of nitrogen-fixing bacteria, 9 to 18 percent of mesophilic actinomycetes, 0.3 to 2 percent of potassium bacteria, 13 to 23 percent of subdigestion bacteria, 0.3 to 2 percent of phosphate solubilizing bacteria, 18 to 24 percent of bacillus megatherium, 0.5 to 3 percent of lactic acid bacteria and 0.5 to 3 percent of saccharomycetes. Fatty acids and sulfides are decomposed through the biphase photosynthetic bacteria through photosynthesis, stink precursor substances are reduced from the source, bifidobacteria and lactic acid bacteria reduce the pH of the environment through acid production, growth of stink-producing putrefying bacteria such as escherichia coli and salmonella is inhibited, release of stink gases such as ammonia and methyl mercaptan is reduced, saccharomycetes generate alcohol through saccharides, and the alcohol content is reduced. The removal rate of hydrogen sulfide and ammonia is greater than or equal to 80%, and the degradation rate of the volatile fatty acid is greater than or equal to 70%.

Escherichia coli bacteriophage and expression and application of endolysin thereof

Resumen de: CN120555369A

The invention discloses expression and application of an Escherichia coli phage and endolysin thereof, and belongs to the technical field of microorganisms, the Escherichia coli phage VB-EcoM-WM is separated from diarrhea cattle manure of a certain cattle farm in Sichuan, the Escherichia coli phage VB-EcoM-WM is preserved in China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 2025810, the endolysin of the Escherichia coli phage VB-EcoM-WM has broad-spectrum lysing property on bacteria, and the endolysin of the Escherichia coli phage VB-EcoM-WM has broad-spectrum lysing property on bacteria. The endolysin is subjected to hydrophobic modification and prokaryotic expression to obtain the fused endolysin protein, so that the cleavage property of the endolysin is more broad-spectrum and efficient. The gene engineering modified fusion protein not only can crack host escherichia coli, but also has a bacteriostatic effect on 15 tested bacteria such as salmonella, streptococcus, staphylococcus and pasteurella. The minimum inhibitory concentration on escherichia coli is 0.1 mu g/ml. The traditional antibiotics can be replaced.

一种基于细菌外膜囊泡的口服疫苗的制备方法及其应用

Resumen de: CN120550103A

一种基于细菌外膜囊泡的口服疫苗制备方法及其应用，可有效应用于制备预防或治疗肠道黏膜病原体感染的药物，克服传统注射型疫苗依从性差、黏膜免疫反应低的问题。首先制备粪产碱杆菌的细菌外膜囊泡，然后制备DSPE‑PEG‑antigen，将两者混合后搅拌，制得OMV‑DSPE‑PEG‑antigen，取菊粉溶于PBS中，加热振荡，冷却至室温，加入OMV‑DSPE‑PEG‑antigen，搅拌，放置，得成品口服疫苗。制备工艺简单，方法稳定可靠，易操作，生产成本低，制备的基于细菌外膜囊的口服疫苗可有效激发肠道黏膜免疫应答，预防黏膜病原体的感染，经济和社会效益显著。

Lateral flow chromatography kit for high-sensitivity quantitative detection of salmonella enteritidis

Resumen de: CN120539398A

The invention belongs to the technical field of food microorganism detection, and provides a lateral flow chromatography kit for high-sensitivity quantitative detection of salmonella enteritidis, which comprises a salmonella enteritidis RPA primer group and a lateral flow chromatography test strip, raman label streptavidin, a Digoxin antibody and a streptavidin antibody are coated on the lateral flow chromatography test strip. The reporter probe is combined on the release pad of the flow measurement chromatography test strip, has two characteristics of colorimetry and SERS (Surface Enhanced Raman Scattering), can finish simultaneous qualitative and quantitative detection of pathogenic bacteria, and improves the detection sensitivity; and the Digoxin antibody and the streptavidin antibody are respectively combined on the detection line and the quality control line. The kit does not need to use large experimental equipment in the whole detection process, is high in detection accuracy and good in specificity, and is very suitable for real-time detection under the condition of relatively low development level.

Biological bacteriostatic agent and preparation method thereof

Resumen de: CN120536277A

The invention discloses a biological bacteriostatic agent and a preparation method thereof, and the preparation method comprises the following steps: step one to step three, inoculating lactic acid bacteria into a liquid fermentation culture medium, and carrying out three-stage fermentation culture; step 4, after the third-stage seed fermentation is finished, performing high-speed centrifugation on the fermentation liquid to obtain a bacterial sludge compound; 5, uniformly mixing the bacterial sludge compound with a protective agent, and performing freeze drying to obtain microbial freeze-dried powder; and 6, uniformly mixing the microbial freeze-dried powder, the auxiliary agent and the auxiliary factor to obtain the biological bacteriostatic agent. The biological bacteriostatic agent prepared by the method disclosed by the invention has remarkable bacteriostatic and bactericidal effects on various pathogenic bacteria, such as escherichia coli, salmonella and staphylococcus aureus; and main antibacterial substances come from lactic acid bacteria and metabolites thereof, so that pathogenic bacteria do not generate drug resistance to the antibacterial substances. The natural components are adopted for fermentation preparation, no chemical component is contained, the environment-friendly effect is achieved, and safety is high; and the preparation method is simple and easy for industrial production.

Nano-enzyme composite material for detecting pathogenic microorganisms in complex matrix and application of nano-enzyme composite material

Resumen de: CN120522382A

The invention discloses a nano-enzyme composite material for detecting pathogenic microorganisms in a complex matrix and application of the nano-enzyme composite material, and belongs to the technical field of pathogen detection. The kit containing the nano-enzyme composite material provided by the invention can realize accurate detection of food-borne pathogenic bacteria in a complex matrix, and has an excellent visual detection effect. And the environment-stable storage performance is excellent and can be up to 60 days. Excellent catalytic activity, stability and selectivity are shown in the aspect of detecting escherichia coli, staphylococcus aureus, vibrio parahaemolyticus and salmonella typhimurium. According to the invention, rapid and reliable detection can be realized, and the detection limit of different pathogens in a PB buffer solution (pH 7.2) is 2-7CFU/mL.

Lead-resistant lactobacillus salivarius Pb214 and application thereof

Resumen de: CN120519328A

The invention belongs to the technical field of lead adsorption, and relates to lead-resistant lactobacillus salivarius Pb214 and application thereof. A new lead-resistant lactobacillus salivarius Pb214 is separated from cecum contents of healthy broilers, the classification name of the lead-resistant lactobacillus salivarius Pb214 is Lactobacillus salivarius, the preservation number of the lead-resistant lactobacillus salivarius Pb214 is CGMCC (China General Microbiological Culture Collection Center) NO.33992, and the lead-resistant lactobacillus salivarius Pb214 is preserved in China General Microbiological Culture Collection Center on March 27, 2025. Meanwhile, experiments prove that the maximum tolerance lead concentration of the lactobacillus salivarius is 1000mg/L, the average lead adsorption rate of the lactobacillus salivarius to a 5mg/L lead solution (pH 5) is 94.9%, the lead adsorption rate is the highest and reaches 96.33% when the pH is 7, and the lactobacillus salivarius can tolerate 0.3% cholate and also can inhibit the growth of salmonella pullorum and staphylococcus aureus. Therefore, the lead-resistant lactobacillus salivarius can be used for removing the lead metal element in a matrix, and the matrix can be soil, feed, a culture medium and other substances needing lead removal.

Antibacterial peptide Meijia-1 and application thereof

Resumen de: CN120518710A

The invention belongs to the technical field of biology, and particularly discloses an antibacterial peptide Meijia-1 and application thereof. The amino acid sequence of the antibacterial peptide is as follows: arginine, glycine, arginine, phenylalanine, glycine, arginine, phenylalanine, leucine, lysine, lysine, valine, arginine, arginine, phenylalanine, isoleucine, proline, lysine and valine. The antibacterial peptide Meijia-1 has better antibacterial activity on gram-positive bacteria (staphylococcus aureus) and gram-negative bacteria (escherichia coli and salmonella), and has the characteristics of heat resistance, salt resistance, acid and alkali resistance, repeated freezing and thawing resistance, serum resistance, organic solvent resistance and pepsin resistance. Therefore, the antibacterial peptide Meijia-1 has wide application prospects in the fields of pathogenic infection resistance, animal feed, food preservation and preservatives, cosmetics, detergents, disinfectants, pesticides, antibacterial molecular materials and the like.

表达FLIC或FLIC-HIL2的减毒禽沙门氏菌及其用途

Resumen de: WO2024155027A1

The present invention relates to an attenuated Salmonella gallinarum expressing FliC or FliC-hiL2 and use thereof. The Salmonella strain according to the present invention has excellent immune activity and exhibits excellent anti-cancer efficacy, and thus can be used as a therapeutic agent for cancer together with or independently of existing anti-cancer drugs.

Application of tea polyphenol in yellow tea in bacterium inhibition

Resumen de: CN120514781A

The invention relates to the technical field of application of natural active substances, in particular to application of tea polyphenol in yellow tea in inhibition of bacteria, gram-positive bacteria comprise staphylococcus aureus, bacillus subtilis, enterococcus faecalis and enterococcus faecium. The gram-negative bacteria comprise escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, proteus mirabilis, salmonella and acinetobacter baumannii. The bacteriostatic activity and related mechanism of the tea polyphenol in the yellow tea are systematically studied, the bacteriostatic effect of the tea polyphenol in the yellow tea on gram-negative bacteria and gram-negative bacteria is proved, and the bacteriostatic mechanism of the tea polyphenol in the yellow tea on bacteria is disclosed through bacteriostatic experiments of the tea polyphenol on different bacteria, so that the bacteriostatic effect of the tea polyphenol in the yellow tea on the gram-negative bacteria and the bacteriostatic effect of the tea polyphenol in the yellow tea on the gram-negative bacteria are proved. The bacteriostatic activity and related mechanisms of the tea polyphenol in the yellow tea are systematically researched, the development of potential clinical medicinal value and edible value of the tea polyphenol is facilitated, and a foundation is laid for the application of the tea polyphenol in the fields of food, medicine and the like.

Fusion protein H3-OtTx1a, construction method and application

Resumen de: CN120518775A

The invention relates to the technical field of biology, in particular to fusion protein, a construction method and application. A new fusion gene is constructed by adopting an SOE-PCR technology for the first time, the fusion protein H3-OtTx1a is obtained by expression in a suitable expression system, the functions of parent proteins of the fusion protein H3-OtTx1a are integrated, the antibacterial activity of the fusion protein H3-OtTx1a is higher than that of hermetia illucens antibacterial peptide H3 and spider peptide OtTx1a, and the fusion protein H3-OtTx1a has good thermal stability, acid-base stability and endogenous protease degradation resistance, and can be used for preparing the antibacterial peptide H3 and spider peptide OtTx1a. Growth of enterobacter, salmonella and staphylococcus aureus can be obviously inhibited, and the compound has wide application prospects in the fields of food, hygienic products, cosmetics, biopesticides, biological feed additives or natural food preservatives and the like.

Application of synanthrin in improving action efficiency of ampicillin on drug-resistant salmonella

Resumen de: CN120514728A

The invention discloses application of synanthrin in improving the action efficiency of ampicillin on drug-resistant salmonella, and relates to the technical field of medical biology. Researches show that synanthrin does not have an inhibiting effect on salmonella, but synanthrin and ampicillin are used together, the inhibiting effect of ampicillin on salmonella can be remarkably improved, and same conclusions are drawn by in-vitro tests and in-vivo tests. According to the invention, the use of antibiotics can be reduced, and a new research direction is provided for the prevention and treatment of salmonella.

ANTI-TUMOR COMBINATION VACCINE

Resumen de: WO2025171792A1

Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.

METHOD FOR MAKING PASTEURIZED IN-SHELL POACHED EGGS

Resumen de: WO2025175111A1

Two stage heated water treatment of shell eggs results in-shell poached eggs. The in-shell poached are sufficiently cooked so when the eggs are cracked onto a plate the eggs have the characteristics of conventional poached eggs without further cooking and need only to be warmed for consumption. The in-shell poached eggs are also pasteurized in the shell to meet the FDA and WHO requirement of a 5-log reduction of Salmonella Enteritidis.

METHOD FOR MAKING PASTEURIZED IN-SHELL POACHED EGGS

Resumen de: US2025261659A1

Two stage heated water treatment of shell eggs results in-shell poached eggs. The in-shell poached are sufficiently cooked so when the eggs are cracked onto a plate the eggs have the characteristics of conventional poached eggs without further cooking and need only to be warmed for consumption. The in-shell poached eggs are also pasteurized in the shell to meet the FDA and WHO requirement of a 5-log reduction of Salmonella Enteritidis.

BACTOFECTION

Resumen de: CN120051482A

The present invention relates to a modified live attenuated Gram-negative bacterium wherein the bacterium has been modified such that an RNA molecule can be safely and efficiently delivered to a target eukaryotic cell. Thus, the present invention relates to a bacterial delivery system and various uses and methods thereof.

-12 Recombinant Expression Vector for Secretion of IL-12 and Attenuated Salmonella Transformed Therewith

Resumen de: KR20240015036A

The present invention relates to a recombinant expression vector for secretion of ifn-03b2# protein and an attenuated salmonella strain transformed by the same. provided are a recombinant expression vector comprising a flgm gene, an ifn-03b2# gene, and a flhdc gene, an attenuated salmonella strain transformed by the same, and a pharmaceutical composition for treating cancer comprising the attenuated salmonella strain as an active ingredient.

mvIIA Recombinant Expression Vector for Secretion of mvIIA and Attenuated Salmonella Transformed Therewith

Resumen de: KR20240015036A

The present invention relates to a recombinant expression vector for secretion of ifn-03b2# protein and an attenuated salmonella strain transformed by the same. provided are a recombinant expression vector comprising a flgm gene, an ifn-03b2# gene, and a flhdc gene, an attenuated salmonella strain transformed by the same, and a pharmaceutical composition for treating cancer comprising the attenuated salmonella strain as an active ingredient.

Phage tail spike recombinant protein fused with silica binding domain or fluorescent protein for detection of Salmonella and method for producing thereof

Resumen de: WO2025170108A1

The present invention relates to identifying and engineering a tail spike protein gene from a genome of bacteriophage SFP10 infected with a Salmonella strain, purifying and producing a recombinant protein using mSFP10TSP, which is a recombinant protein formulation for detecting Salmonella enterica, EGFP-mSFP10TSP fused with a green fluorescent protein, and SiBD-mSFP10TSP fused with an SiBD, and thereby specifically detecting the Salmonella strain.

Molecular detection method of salmonella and application thereof

Resumen de: CN120505437A

The invention relates to the technical field of salmonella detection, in particular to a salmonella molecular detection method and application thereof, and the salmonella molecular detection method comprises the following steps: S1, sample treatment: extracting DNA in a to-be-detected sample; step S2, primer design and synthesis: specific primers are designed for the invA gene, the hilA gene and the stn gene of salmonella; s3, multiple PCR reaction: taking the DNA extracted in the step S1 as a template, and carrying out multiple PCR amplification by adopting the primer in the step S2; s4, fluorescent probe hybridization: hybridizing a PCR amplification product in the step S3 with a fluorescent labeled probe; s5, fluorescence signal detection: detecting a fluorescence signal after hybridization through a fluorescence detector, and judging whether the sample contains salmonella or not according to the signal. According to the salmonella molecular detection method provided by the invention, a technology of combining multiple PCR with fluorescent probe hybridization is adopted, a plurality of conserved genes of salmonella can be detected at the same time, and the detection specificity and sensitivity are improved.

Hybridoma cell strain secreting anti-salmonella abortus groEL protein monoclonal antibody, monoclonal antibody and application thereof

Nº publicación: CN120505281A 19/08/2025

Solicitante:

HARBIN VETERINARY RES INSTITUTE CAAS HARBIN BRANCH OF CHINA ANIMAL HEALTH AND EPIDEMIOLOGY CENTER
\u4E2D\u56FD\u519C\u4E1A\u79D1\u5B66\u9662\u54C8\u5C14\u6EE8\u517D\u533B\u7814\u7A76\u6240\uFF08\u4E2D\u56FD\u52A8\u7269\u536B\u751F\u4E0E\u6D41\u884C\u75C5\u5B66\u4E2D\u5FC3\u54C8\u5C14\u6EE8\u5206\u4E2D\u5FC3\uFF09

Resumen de: CN120505281A

The invention discloses a hybridoma cell strain secreting an anti-salmonella abortus groEL protein monoclonal antibody, the monoclonal antibody and application of the hybridoma cell strain. The hybridoma cell strain is named as E11, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the strain preservation number of the hybridoma cell strain is CGMCC No.46349. According to the present invention, the salmonella universal cELISA antibody detection method capable of being applied to different animals is established by using the E11 MAb secreted by the hybridoma cell strain secreting the anti-horse salmonella abortus groEL protein monoclonal antibody and the horse salmonella abortus groEL protein; the salmonella comprises salmonella abortus (S.Abortuqui), salmonella typhimurium (S.Typhi), salmonella dublin (S.Dublin) and salmonella enteritidis (S.Enteridis), so that the method disclosed by the invention has the advantages of good specificity and broad spectrum. The invention provides an effective technical means for diagnosis, prevention and control of salmonellosis of different animals clinically.